PROLOR Biotech to Present Positive Results From Preclinical Studies of Long-Acting Clotting Factor VIIa-CTP at ISTH 2013

    PROLOR Biotech to Present Positive Results From Preclinical Studies of
              Long-Acting Clotting Factor VIIa-CTP at ISTH 2013

--New Data Show a Simple Subcutaneous Injection of Factor VIIa-CTP Could
Potentially Replace Current Therapies Administered Via Infusion--

PR Newswire

AMSTERDAM and NES-ZIONA, Israel, July 3, 2013

AMSTERDAM and NES-ZIONA, Israel, July 3, 2013 /PRNewswire/ --PROLOR Biotech,
Inc. (NYSE MKT: PBTH), today announced that the company will present new
results from preclinical studies of its long-acting clotting factor VIIa
(Factor VIIa-CTP), a next-generation investigational therapy in advanced
preclinical development for the potential treatment of hemophilia. The data
provide further evidence that Factor VIIa-CTP has the potential to be
administered by subcutaneous (SC) injection as well as intravenously (IV),
which would facilitate its prophylactic use by patients on an ongoing basis.
The study results will be discussed in an oral presentation at the XXIV
Congress of the International Society of Hemostasis and Thrombosis (ISTH).

Currently available commercial factor VIIa must be administered through IV
infusion, which can be onerous for patients. This limits its use for
prophylactic treatment and can require frequent administrations if patients
are treated only "on demand" when a bleeding episode occurs.

The new preclinical results being presented at the ISTH Congress further
confirm the efficacy of PROLOR's long-acting Factor VIIa-CTP and show that it
has the potential to be administered using a simple SC injection. The
combination of a long-acting product coupled with the ability to be
administered by SC injection could change the way that factor VIIa is used,
potentially allowing individuals with hemophilia to self-administer the drug
at home on a prophylactic basis, improving their quality of life and
potentially reducing the need for on-demand treatment of bleeding episodes.

Dr. Abraham Havron, CEO of PROLOR, commented, "We have previously presented
data in animal models of hemophilia showing that Factor VIIa-CTP demonstrated
long-acting properties compared to commercially available factor VIIa. These
new data reflect our extensive recent work confirming those data and also
assessing the potential of hGH-CTP to be administered by SC injection, which
could be transformative for some hemophilia patients. Based on these exciting
results, we expect to initiate two independent clinical programs for Factor
VIIa-CTP in 2014—one for on-demand and prophylactic treatment of hemophilia
using the IV route and a second for prophylactic treatment using the SC

The data will be presented by Dr. Gili Hart, Vice President, Pre-Clinical
Development and Clinical Pharmacology at PROLOR and head of the company's
long-acting clotting factors program. Dr. Hart's presentation, "A long-acting
FVIIa-CTP proposing an improved prophylactic and on-demand treatment for
hemophilic patients following SC and IV administration - evaluation in animal
models," will be presented on July 4, 2013, at 9:15 am local time. The XXIV
ISTH Congress is being held June 29-July 4, 2013, in Amsterdam. For more
information, visit

About Hemophilia
Patients with hemophilia do not produce adequate amounts of the clotting
factors that are necessary for effective blood clotting. In severe
hemophiliacs even a minor injury can result in blood loss that may continue
for days or weeks, with the potential for debilitating permanent damage to
joints and other organs and premature death. According to the World Health
Organization, more than 400,000 people worldwide have hemophilia. Commercially
available recombinant clotting factors have enabled many hemophiliacs to live
near-normal lives, but frequent injections, infusions and/or blood
transfusions may be required.

Planned PROLOR Merger with OPKO Health
On April 24, 2013, OPKO Health, Inc. (NYSE: OPK) and PROLOR Biotech announced
that the companies had signed a definitive merger agreement under which OPKO
will acquire PROLOR in an all-stock transaction. Under the terms of the
agreement, which has been approved by the boards of directors of both
companies, holders of PROLOR common stock will receive 0.9951 shares of OPKO
common stock for each share of PROLOR stock.PROLOR and OPKO expect the
transaction to be completed during the second half of 2013.Closing of the
transaction is subject to certain conditions, including the approval of the
merger agreement by PROLOR's stockholders, approval of the issuance of the
share consideration by OPKO's stockholders, the receipt of antitrust approval
and other customary closing conditions.

Additional Information and Where to Find It
This communication does not constitute an offer to sell or the solicitation of
an offer to buy any securities or a solicitation of any vote or approval nor
shall there be any sale of securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such jurisdiction.In connection with the
proposed merger between PROLOR and OPKO, OPKO has filed with the Securities
and Exchange Commission (the "SEC") a Registration Statement on Form S-4 that
includes a proxy statement of OPKO and PROLOR and a prospectus of OPKO.
Stockholders of OPKO and PROLOR are urged to read the joint proxy
statement/prospectus regarding the proposed transaction, as well as other
documents filed with the SEC, because they contain important information.
Stockholders of OPKO and PROLOR may obtain a copy of the joint proxy
statement/prospectus, as well as other filings containing information about
PROLOR and OPKO, without charge, at the SEC's website (
Stockholders of OPKO and PROLOR may also obtain copies of all documents filed
with the SEC, without charge, by directing a request to Shachar Shlosberger,
PROLOR Biotech, Inc., 7 Golda Meir Street, Weizmann Science Park, Nes-Ziona,
Israel 74140, telephone (+972) 8-930-0051, or Steven D. Rubin or Juan F.
Rodriguez, OPKO Health, Inc., 4400 Biscayne Blvd., Miami, Florida, telephone
(305) 575-4100.

Investors may obtain copies of all documents filed with the SEC regarding this
transaction, free of charge, at the SEC's website ( They may
also obtain these documents, free of charge, from OPKO's website
( or from PROLOR's website (

Participants in the Merger Solicitation
PROLOR, OPKO and their respective directors and executive officers may be
deemed to be participants in the solicitation of proxies from the stockholders
of PROLOR and OPKO in connection with the proposed transaction.Information
about PROLOR's directors and executive officers is set forth in its proxy
statement for its 2013 Annual Meeting of Stockholders, which was filed with
the SEC on April 25, 2013.These documents are available free of charge at the
SEC's website at, or by going to PROLOR's Investor Relations page
on its corporate website at Information about OPKO's
directors and executive officers is set forth in Amendment No. 1 to its Annual
Report on Form 10-K for the year ended December 31, 2012, which was filed with
the SEC on April 29, 2013. These documents are available free of charge at
the SEC's website at, or by going to OPKO's Investor Relations
page on its corporate website at information
regarding the interests of participants in the solicitation of proxies in
connection with the transaction will be included in the joint proxy

PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying
unique technologies, including patented CTP technology and its long-acting
reversible-pegylation technology, primarily to develop longer-acting
proprietary versions of already approved therapeutic proteins that currently
generate billions of dollars in annual global sales. The CTP technology is
applicable to virtually all proteins. PROLOR is developing a long-acting
version of human growth hormone, which is in a Phase IIl clinical trial. It
also is developing long-acting versions of factor VIIa and factor IX for
hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and
obesity, all of which are in preclinical development. For more information,

Safe Harbor Statement: This press release contains forward-looking
statements, which may be identified by words such as "expects," "plans,"
"projects," "will," "may," "anticipates," "believes," "should," "would",
"intends," "estimates," "suggests," "has the potential to" and other words of
similar meaning, including statements regarding the results of current
clinical studies and preclinical experiments and the effectiveness of PROLOR's
long-acting protein programs, which are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Investors
are cautioned that forward-looking statements involve risks and uncertainties
that may affect PROLOR's business and prospects, including the risks that
PROLOR may not succeed in generating any revenues or developing any commercial
products, including any long-acting versions of human growth hormone,
erythropoietin, interferon beta, GLP-1 and other products; that the
long-acting products in development may fail, may not achieve the expected
results or effectiveness and/or may not generate data that would support the
approval or marketing of these products for the indications being studied or
for other indications; that ongoing studies may not continue to show
substantial or any activity; that the actual dollar amount of any grants from
Israel's Office of the Chief Scientist is uncertain and is subject to policy
changes of the Israeli government, and that such grants may be insufficient to
assist with product development; and other risks and uncertainties that may
cause results to differ materially from those set forth in the forward-looking
statements. The results of clinical trials in humans may produce results that
differ significantly from the results of clinical and other trials in animals.
The results of early-stage trials may differ significantly from the results of
more developed, later-stage trials. The development of any products using the
CTP platform technology could also be affected by a number of other factors,
including unexpected safety, efficacy or manufacturing issues, additional time
requirements for data analyses and decision making, the impact of
pharmaceutical industry regulation, the impact of competitive products and
pricing and the impact of patents and other proprietary rights held by
competitors and other third parties. In addition to the risk factors
described above, investors should consider the economic, competitive,
governmental, technological and other factors discussed in PROLOR's filings
with the Securities and Exchange Commission. The forward-looking statements
contained in this press release speak only as of the date the statements were
made, and we do not undertake any obligation to update forward-looking
statements, except as required under applicable law.

Shai Novik, President            Barbara Lindheim
PROLOR Biotech, Inc.            BLL Partners, LLC
Tel: +1 866 644-7811            +1 212 584-2276


Press spacebar to pause and continue. Press esc to stop.